Home > News > Starpharma gets US nod to work on HIV gel
November 19th, 2003
Starpharma gets US nod to work on HIV gel
Abstract:
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday. Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration. He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.
Source:
The Age
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||